Orphan Drug Designation by US FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma November 12, 2024
Autologous Dendritic Cell Vaccine DOC1021 Yields 93% 12-Month Survival for GBM Patients October 8, 2024
Diakonos Oncology Announces Final Closing of Oversubscribed $11.4M Seed Financing to Advance DOC1021 into a Ph 2 Clinical Trial October 8, 2024
Ph 1 Data of Concurrent Paxalisib + RT in Patients with Solid Tumor Brain Mets or Leptomeningeal Mets Harboring PI3K Pathway Mutations announced October 8, 2024
Pathos Expands Pipeline With Worldwide License of Ph 2-ready Program, a Brain-penetrant, PRMT5 Inhibitor August 22, 2024
Recruitment completed for CLINGLIO, the Ph 2b/3 Clinical Trial of idroxioleic acid (LAM561) in combination with RT and TMZ for adults with newly diagnosed GBM June 18, 2024
FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma June 4, 2024
Vebreltinib approved in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene May 1, 2024
OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for R/R BRAF-altered Pediatric Low-Grade Glioma (pLGG) May 1, 2024
Data from Ph 1 Trial of MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma published March 12, 2024
